Table 1.
The clinical and pathologic characteristics at baseline.
| Characteristic | No. of patients (%) before PSM | No. of patients (%) after PSM | |||||
|---|---|---|---|---|---|---|---|
| Overall (n = 1322) | Non FH (n = 1042) | FH (n = 280) | P-Value | Non FH (n = 215) | FH (n = 215) | P-Value | |
| Age | 0.148 | 1.000 | |||||
| ≤58 years | 803 (60.7) | 622 (59.7) | 181 (64.6) | 139 (64.7) | 140 (65.1) | ||
| >58 years | 519 (39.3) | 420 (40.3) | 99 (35.4) | 76 (35.3) | 75 (34.9) | ||
| Gender | 0.628 | 0.910 | |||||
| Females | 296 (22.4) | 230 (22.1) | 66 (23.6) | 52 (24.2) | 50 (23.3) | ||
| Males | 1026 (77.6) | 812 (77.9) | 214 (76.4) | 163 (75.8) | 165 (76.7) | ||
| Smoking | 0.575 | 0.919 | |||||
| Never | 472 (35.7) | 368 (35.3) | 104 (37.1) | 73 (33.9) | 75 (34.9) | ||
| Ever (former + current) | 850 (64.3) | 674 (64.7) | 176 (62.9) | 142 (66.1) | 140 (65.1) | ||
| Alcohol | 0.103 | 1.00 | |||||
| Never | 868 (65.7) | 696 (66.8) | 172 (61.4) | 137 (63.7) | 138 (64.2) | ||
| Ever (former + current) | 453 (34.3) | 346 (33.2) | 108 (38.6) | 78 (36.3) | 77 (35.8) | ||
| Dysphagia | <0.001 | 0.772 | |||||
| No | 580 (43.9) | 430 (41.3) | 150 (53.6) | 105 (48.8) | 109 (50.7) | ||
| Yes | 742 (56.1) | 612 (58.7) | 130 (46.4) | 110 (51.2) | 106 (49.3) | ||
| Radicality of surgery | 0.509 | 1.000 | |||||
| R0 | 1265 (95.7) | 999 (95.9) | 266 (95.0) | 212 (98.6) | 213 (99.1) | ||
| R1 | 57 (4.3) | 43 (4.1) | 14 (5.0) | 3 (1.4) | 2 (0.9) | ||
| pT stage | 0.001 | 0.921 | |||||
| T1-2 | 433 (33.5) | 326 (31.3) | 117 (41.8) | 85 (39.5) | 83 (38.6) | ||
| T3-4 | 879 (66.5) | 716 (68.7) | 163 (58.2) | 130 (60.5) | 132 (61.4) | ||
| pN stage | 0.022 | 0.847 | |||||
| N0 | 641(48.5) | 488 (46.8) | 153 (54.6) | 117 (54.4) | 114 (53.0) | ||
| N1-3 | 681(51.5) | 554 (53.2) | 127 (45.4) | 98 (45.6) | 101 (47.0) | ||
| Differentiation | 0.334 | 0.914 | |||||
| G1-2 | 942 (71.3) | 749 (71.9) | 193 (68.9) | 156 (72.6) | 158 (73.5) | ||
| G3 | 380 (28.7) | 293 (28.1) | 87 (31.1) | 59 (27.4) | 57 (26.5) | ||
| Tumor location | 0.629 | 0.906 | |||||
| Upper | 295 (22.3) | 227 (21.8) | 68 (24.3) | 43 (20.0) | 44 (20.5) | ||
| Middle | 907 (68.6) | 721 (69.2) | 186 (66.4) | 162 (75.4) | 159 (74.0) | ||
| Lower | 120 (9.1) | 94 (9.0) | 26 (9.3) | 10 (4.6) | 12 (5.5) | ||
| TNM stage | 0.006 | 0.843 | |||||
| I-II | 729 (55.1) | 554 (53.2) | 175 (62.5) | 133 (61.9) | 130 (60.5) | ||
| III | 593 (44.9) | 488(46.8) | 105(37.5) | 82 (38.1) | 85 (39.5) | ||
| Adjuvant therapy | 0.414 | 1.000 | |||||
| No | 1035 (78.3) | 821 (78.8) | 214 (76.4) | 178 (82.8) | 177 (82.3) | ||
| Yes | 287 (21.7) | 221 (21.2) | 66 (23.6) | 37 (17.2) | 38 (17.7) | ||
PSM, Propensity Score Matching; FH, family history of cancer.
Bold values are statistically significant (P < 0.05).